Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.

Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK, Burch D, Brand B, Free J, Asgharnejad M, Wang GJ, Telang F, Hubbard B, Jayne M, King P, Carter P, Carter S, Xu Y, Shea C, Muench L, Alexoff D, Shumay E, Schueller M, Warner D, Apelskog-Torres K.

Neuropsychopharmacology. 2010 Feb;35(3):623-31. doi: 10.1038/npp.2009.167. Epub 2009 Nov 4.

2.

Brain monoamine oxidase A inhibition in cigarette smokers.

Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP.

Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14065-9.

3.

Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.

Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L.

Neuropsychopharmacology. 2015 Feb;40(3):650-7. doi: 10.1038/npp.2014.214. Epub 2014 Sep 24.

4.

Non-MAO A binding of clorgyline in white matter in human brain.

Fowler JS, Logan J, Ding YS, Franceschi D, Wang GJ, Volkow ND, Pappas N, Schlyer D, Gatley SJ, Alexoff D, Felder C, Biegon A, Zhu W.

J Neurochem. 2001 Dec;79(5):1039-46.

5.

SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.

Kan JP, Steinberg R, Mouget-Goniot C, Worms P, Bizière K.

J Pharmacol Exp Ther. 1987 Jan;240(1):251-8.

PMID:
3100771
6.

Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study.

Sacher J, Houle S, Parkes J, Rusjan P, Sagrati S, Wilson AA, Meyer JH.

J Psychiatry Neurosci. 2011 Nov;36(6):375-82. doi: 10.1503/jpn.100117.

7.

Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.

Gerardy J.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):793-802.

PMID:
7938567
8.

Reversibility of the interaction of CGP 11305 A with MAO A in vivo.

Waldmeier PC, Feldtrauer JJ, Stoecklin K, Paul E.

Eur J Pharmacol. 1983 Oct 14;94(1-2):101-8.

PMID:
6197309
9.

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

Garcia-Miralles M, Ooi J, Ferrari Bardile C, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA.

Exp Neurol. 2016 Apr;278:4-10. doi: 10.1016/j.expneurol.2016.01.019. Epub 2016 Jan 26.

10.
12.

Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Fowler JS, Logan J, Volkow ND, Wang GJ.

Mol Imaging Biol. 2005 Nov-Dec;7(6):377-87. Review.

PMID:
16265597
13.

Inhibition of type A monoamine oxidase by coptisine in mouse brain.

Ro JS, Lee SS, Lee KS, Lee MK.

Life Sci. 2001 Dec 28;70(6):639-45.

PMID:
11833714
15.

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.

Chiuccariello L, Cooke RG, Miler L, Levitan RD, Baker GB, Kish SJ, Kolla NJ, Rusjan PM, Houle S, Wilson AA, Meyer JH.

Int J Neuropsychopharmacol. 2015 Aug 27;19(1). pii: pyv078. doi: 10.1093/ijnp/pyv078.

16.

Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.

Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, et al.

Eur J Clin Pharmacol. 1991;40(2):169-73.

PMID:
1906004
17.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16.

18.

MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.

Bergström M, Westerberg G, Németh G, Traut M, Gross G, Greger G, Müller-Peltzer H, Safer A, Eckernäs SA, Grahnér A, Långström B.

Eur J Clin Pharmacol. 1997;52(2):121-8.

PMID:
9174681
19.

SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.

Aubin N, Barneoud P, Carter C, Caille D, Sontag N, Marc C, Lolivier J, Gardes A, Perron C, Le Kim A, Charieras T, Pandini M, Burnier P, Puech F, Jegham S, George P, Scatton B, Curet O.

J Pharmacol Exp Ther. 2004 Sep;310(3):1171-82. Epub 2004 Jun 3.

20.

Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers.

Fowler JS, Logan J, Wang GJ, Volkow ND, Telang F, Zhu W, Franceschi D, Shea C, Garza V, Xu Y, Ding YS, Alexoff D, Warner D, Netusil N, Carter P, Jayne M, King P, Vaska P.

J Nucl Med. 2005 Sep;46(9):1414-20.

Supplemental Content

Support Center